• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单侧甲状腺全切除术:对于AMES低危型乳头状甲状腺癌患者来说,这是足够的手术治疗方式吗?

Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?

作者信息

Hay I D, Grant C S, Bergstralh E J, Thompson G B, van Heerden J A, Goellner J R

机构信息

Department of Surgery, Mayo Clinic and Medical Center, Rochester, Minn., USA.

出版信息

Surgery. 1998 Dec;124(6):958-64; discussion 964-6.

PMID:9854569
Abstract

BACKGROUND

Controversy continues regarding the optimal extent of primary thyroid resection in most patients with papillary thyroid carcinoma (PTC), who are at minimal risk of cause-specific mortality (CSM). This study was designed to compare CSM and recurrence rates after either unilateral lobectomy (UL) or bilateral lobar resection (BLR) in patients with PTC considered low risk by AMES criteria.

METHODS

Outcome was studied in 1685 patients initially treated during 1940 through 1991 and followed for up to 54 postoperative years (mean, 18 years). One thousand six hundred fifty-six patients (98%) had complete primary tumor resection; 634 (38%) had involvement of regional nodes. One hundred ninety-five patients (12%) had UL; BLR accounted for 1468 (near-total 60%; total thyroidectomy 18%).

RESULTS

Thirty-year rates for CSM and distant metastasis were 2% and 3%, respectively. Twenty-year rates for local recurrence and nodal metastasis were 4% and 8%, respectively. There were no significant differences in CSM or distant metastasis rates between UL and BLR (P > .2). After UL, 20-year rates for local recurrence and nodal metastasis were 14% and 19%, significantly higher (P = .0001) than the 2% and 6% rates seen after BLR.

CONCLUSIONS

UL was not associated with higher CSM rates, but it was associated with a significantly higher risk of locoregional recurrence. Thus BLR probably represents a preferable initial surgical approach to patients with low-risk PTC.

摘要

背景

对于大多数甲状腺乳头状癌(PTC)患者,其特定病因死亡率(CSM)风险极低,关于原发性甲状腺切除的最佳范围仍存在争议。本研究旨在比较根据AMES标准被认为低风险的PTC患者行单侧甲状腺叶切除术(UL)或双侧甲状腺叶切除术(BLR)后的CSM和复发率。

方法

对1685例于1940年至1991年期间接受初始治疗并随访长达术后54年(平均18年)的患者的结局进行研究。1656例患者(98%)实现了原发性肿瘤的完全切除;634例(38%)有区域淋巴结受累。195例患者(12%)接受了UL;1468例患者接受了BLR(近全切除术60%;甲状腺全切除术18%)。

结果

CSM和远处转移的30年发生率分别为2%和3%。局部复发和淋巴结转移的20年发生率分别为4%和8%。UL和BLR之间的CSM或远处转移率无显著差异(P>.2)。UL后,局部复发和淋巴结转移的20年发生率分别为14%和19%,显著高于BLR后的2%和6%(P=.0001)。

结论

UL与较高的CSM发生率无关,但与局部区域复发的显著较高风险相关。因此,BLR可能是低风险PTC患者更可取的初始手术方法。

相似文献

1
Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?单侧甲状腺全切除术:对于AMES低危型乳头状甲状腺癌患者来说,这是足够的手术治疗方式吗?
Surgery. 1998 Dec;124(6):958-64; discussion 964-6.
2
Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989.1940年至1989年期间,在一家机构接受治疗的300例病理肿瘤-淋巴结-转移分期为III期的乳头状甲状腺癌患者中,初次手术对其预后的影响。
Surgery. 1999 Dec;126(6):1173-81; discussion 1181-2. doi: 10.1067/msy.2099.101435.
3
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.梅奥诊所60年(1940 - 1999年)间治疗的甲状腺乳头状癌:2444例连续治疗患者的初始治疗时间趋势及长期预后
World J Surg. 2002 Aug;26(8):879-85. doi: 10.1007/s00268-002-6612-1. Epub 2002 May 21.
4
Optimizing the treatment of AMES high-risk papillary thyroid carcinoma.优化AMES高危乳头状甲状腺癌的治疗
World J Surg. 2004 Nov;28(11):1103-9. doi: 10.1007/s00268-004-7420-6.
5
Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.甲状腺乳头状癌患者的管理:从梅奥诊所1940年至2000年连续治疗2512例患者的经验中获得的见解。
Trans Am Clin Climatol Assoc. 2002;113:241-60.
6
Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: A meta-analysis.全甲状腺切除术与甲状腺叶切除术作为小的单侧甲状腺乳头状癌的初始手术方式:一项荟萃分析。
Surg Oncol. 2015 Jun;24(2):117-22. doi: 10.1016/j.suronc.2015.04.005. Epub 2015 Apr 22.
7
Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.甲状腺微小乳头状癌:一项为期60年的900例病例研究。
Surgery. 2008 Dec;144(6):980-7; discussion 987-8. doi: 10.1016/j.surg.2008.08.035.
8
Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).儿童和成人甲状腺乳头状癌(PTC):梅奥诊所80年间(1936 - 2015年)连续治疗的4432例患者的初始表现与术后长期结果比较
World J Surg. 2018 Feb;42(2):329-342. doi: 10.1007/s00268-017-4279-x.
9
Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008.215 例儿童和青少年甲状腺乳头癌患者的长期预后:1940 年至 2008 年的治疗结果。
World J Surg. 2010 Jun;34(6):1192-202. doi: 10.1007/s00268-009-0364-0.
10
Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features.对于直径1至4厘米且无临床可识别高危特征的乳头状甲状腺癌,肺叶切除术比全甲状腺切除术更具成本效益。
Ann Surg Oncol. 2016 Oct;23(11):3641-3652. doi: 10.1245/s10434-016-5280-6. Epub 2016 May 24.

引用本文的文献

1
Demographic and Prognostic Factors of the Columnar Cell Variant of Papillary Thyroid Carcinoma: A National Cancer Database Study.甲状腺乳头状癌柱状细胞变体的人口统计学和预后因素:一项国家癌症数据库研究。
Cureus. 2024 Aug 15;16(8):e66913. doi: 10.7759/cureus.66913. eCollection 2024 Aug.
2
Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.甲状腺癌患者的肺叶切除术:智利一家三级中心的经验。
Endocrine. 2024 Nov;86(2):692-698. doi: 10.1007/s12020-024-03905-1. Epub 2024 Jun 14.
3
Theranostic Risk Stratification for Thyroid Cancer in the Genomic Paradigm.
基因组模式下甲状腺癌的诊疗风险分层
Cancers (Basel). 2024 Apr 20;16(8):1585. doi: 10.3390/cancers16081585.
4
Dynamic risk assessment in patients with differentiated thyroid cancer.分化型甲状腺癌患者的动态风险评估。
Rev Endocr Metab Disord. 2024 Feb;25(1):79-93. doi: 10.1007/s11154-023-09857-7. Epub 2023 Nov 28.
5
Three-dimensional ultrasound-based radiomics nomogram for the prediction of extrathyroidal extension features in papillary thyroid cancer.基于三维超声的影像组学列线图预测甲状腺乳头状癌的甲状腺外侵犯特征
Front Oncol. 2023 Aug 23;13:1046951. doi: 10.3389/fonc.2023.1046951. eCollection 2023.
6
Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4 cm papillary thyroid carcinoma.甲状腺 1-4cm 大小的乳头状甲状腺癌患者行甲状腺叶切除术后的血清甲状腺球蛋白检测。
Endocrine. 2023 Aug;81(2):290-297. doi: 10.1007/s12020-023-03346-2. Epub 2023 Mar 13.
7
Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.滤泡性甲状腺癌原发肿瘤大小和 TERT 启动子突变状态用于甲状腺全切术选择的标准。
Ann Surg Oncol. 2023 May;30(5):2916-2925. doi: 10.1245/s10434-022-13089-5. Epub 2023 Jan 13.
8
Long-Term Outcome of Lobectomy for Thyroid Cancer.甲状腺癌肺叶切除术的长期结果
Eur Thyroid J. 2021 Nov;10(6):486-494. doi: 10.1159/000510620. Epub 2020 Sep 29.
9
The incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer-a retrospective cohort study.分化型甲状腺癌术后复发再分层的发生率——一项回顾性队列研究
Gland Surg. 2021 Aug;10(8):2354-2367. doi: 10.21037/gs-21-105.
10
Total thyroidectomy lobectomy in differentiated thyroid cancer: is there a reasonable size cut-off for decision? A narrative review.分化型甲状腺癌的全甲状腺切除术与叶切除术:是否存在合理的决定手术方式的肿瘤大小临界值?一项叙述性综述。
Gland Surg. 2021 Jul;10(7):2275-2283. doi: 10.21037/gs-21-242.